Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
Year: 2021
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.20.02864
Authors: John Mascarenhas, Rami S. Komrokji, Francesca Palandri, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L. Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Odenike, Alessandro M. Vannucchi, Jacqueline Bussolari, Eugene Zhu, Esther Rose, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye M. Feller, Aleksandra Rizo, Jean-Jacques Kiladjian
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Moffitt Cancer Center, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Azienda ospedaliera "Bianchi-Melacrino-Morelli", University Hospital Leipzig, University Medical Centre Mannheim, Fred Hutch Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, University of Florence, Janssen Research & Development (United States), Geron (United States), Hôpital Saint-Louis
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3165929791